BIRB-796 is not an effective ABL(T315I) inhibitor

被引：20

作者：

O'Hare, T ^{[1
]}

Druker, BJ ^{[1
]}

机构：

[1] Oregon Hlth & Sci Univ, Howard Hughes Med Inst, Inst Canc, Portland, OR 97239 USA

来源：

NATURE BIOTECHNOLOGY | 2005年 / 23卷 / 10期

关键词：

D O I：

10.1038/nbt1005-1209

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

引用

页码：1209 / 1210

页数：2

共 8 条

[1] A small molecule-kinase interaction map for clinical kinase inhibitors [J].

Fabian, MA ;

Biggs, WH ;

Treiber, DK ;

Atteridge, CE ;

Azimioara, MD ;

Benedetti, MG ;

Carter, TA ;

Ciceri, P ;

Edeen, PT ;

Floyd, M ;

Ford, JM ;

Galvin, M ;

Gerlach, JL ;

Grotzfeld, RM ;

Herrgard, S ;

Insko, DE ;

Insko, MA ;

Lai, AG ;

Lélias, JM ;

Mehta, SA ;

Milanov, ZV ;

Velasco, AM ;

Wodicka, LM ;

Patel, HK ;

Zarrinkar, PP ;

Lockhart, DJ .

NATURE BIOTECHNOLOGY, 2005, 23 (03) :329-336

[2]

Nagar B, 2002, CANCER RES, V62, P4236

[3] In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants [J].

O'Hare, T ;

Walters, DK ;

Stoffregen, EP ;

Jia, TP ;

Manley, PW ;

Mestan, J ;

Cowan-Jacob, SW ;

Lee, FY ;

Heinrich, MC ;

Deininger, MWN ;

Druker, BJ .

CANCER RESEARCH, 2005, 65 (11) :4500-4505

[4] AMN107: Tightening the grip of imatinib [J].

O'Hare, T ;

Walters, DK ;

Deininger, MWN ;

Druker, BJ .

CANCER CELL, 2005, 7 (02) :117-119

[5] Inhibition of wild-type and mutant Bcr-Abl by AP23464, a potent ATP-based oncogenic protein kinase inhibitor: implications for CML [J].

O'Hare, T ;

Pollock, R ;

Stoffregen, EP ;

Keats, JA ;

Abdullah, OM ;

Moseson, EM ;

Rivera, VM ;

Tang, H ;

Metcalf, CA ;

Bohacek, RS ;

Wang, YH ;

Sundaramoorthi, R ;

Shakespeare, WC ;

Dalgarno, D ;

Clackson, T ;

Sawyer, TK ;

Deininger, MW ;

Druker, BJ .

BLOOD, 2004, 104 (08) :2532-2539

[6] Imatinib inhibits T-cell receptor-mediated T-cell proliferation and activation in a dose-dependent manner [J].

Seggewiss, R ;

Loré, K ;

Greiner, E ;

Magnusson, MK ;

Price, DA ;

Douek, DC ;

Dunbar, CE ;

Wiestner, A .

BLOOD, 2005, 105 (06) :2473-2479

[7] Overriding imatinib resistance with a novel ABL kinase inhibitor [J].

Shah, NP ;

Tran, C ;

Lee, FY ;

Chen, P ;

Norris, D ;

Sawyers, CL .

SCIENCE, 2004, 305 (5682) :399-401

[8] Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl [J].

Weisberg, E ;

Manley, PW ;

Breitenstein, W ;

Brüggen, J ;

Cowan-Jacob, SW ;

Ray, A ;

Huntly, B ;

Fabbro, D ;

Fendrich, G ;

Hall-Meyers, E ;

Kung, AL ;

Mestan, J ;

Daley, GQ ;

Callahan, L ;

Catley, L ;

Cavazza, C ;

Mohammed, A ;

Neuberg, D ;

Wright, RD ;

Gilliland, DG ;

Griffin, JD .

CANCER CELL, 2005, 7 (02) :129-141

← 1 →